December 11, 2006 — The US Food and Drug Administration (FDA) and Baxter Healthcare Corp have warned healthcare professionals regarding the risk for delayed-onset heparin-induced thrombocytopenia (HIT ...
CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Acquires 12-LOX Inhibitor VLX-1005 for the Treatment of HIT In December 2025, Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) announced the ...
Therapeutic-dose heparin appears to benefit noncritically-ill COVID-19 patients, but it does not reduce deaths or other adverse endpoints compared with usual-care thromboprophylaxis if it’s initiated ...
LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today it has introduced in the United States two new presentations of Heparin Sodium in convenient, ready-to-administer Freeflex ® IV bags.
Global Heparin Market OverviewThe Global Heparin Market is projected to grow steadily at a CAGR of approximately 5% by 2026.
A team of researchers developed 3 quality improvement measures embedded in electronic health records (EHRs) to improve care delivery in patients with heparin-induced thrombocytopenia. HIT is known as ...
Thiotepa-Based High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Patients With Recurrent or Progressive CNS Germ Cell Tumors Patients with advanced malignancy (N = 385) were randomly assigned ...
The global heparin market is projected to expand at a steady compound annual growth rate of around 5% through 2031, supported by the rising burden of chronic and life-threatening conditions such as ...
Heparin-induced thrombocytopenia (HIT) is a clinically significant immune-mediated adverse reaction to heparin therapy. It is typified by a reduction in circulating platelets while paradoxically ...
With the recent tariffs imposed by President Donald Trump, experts are warning that new trade barriers could jeopardize the supply of heparin, an inexpensive and widely used anticoagulant critical for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results